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Abstract
Background: Liver transplantation is used to treat patients with irreversible liver failure from a variety of
causes. Long-term survival has been reported, particularly in the paediatric population, with graft survival
longer than 20 years now possible. The goal for paediatric liver transplantation is to increase the longevity
of grafts to match the normal life expectancy of the child. This paper reviews the literature on the current
understanding of ageing of the liver and biomarkers that may predict long-term survival or aid in utilization
of organs.
Methods: Scientific papers published from 1950 to 2013 were sought and extracted from the MEDLINE,
PubMed and University of Melbourne databases.
Results: Hepatocytes appear resistant to the ageing process, but are affected by both replicative
senescence and stress-related senescence. These processes may be exacerbated by the act of trans-
plantation. The most studied biomarkers are telomeres and SMP-30.
Conclusion: There are many factors that play a role in the ageing of the liver. Further studies into
biomarkers of ageing and their relationship to the chronological age of the liver are required to aid in
predicting long-term graft survival and utilization of organs.
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Introduction
Excellent 10-year survival rates of up to 82% can be achieved in
paediatric liver transplantation,1 however, the goal is for paediat-
ric transplant recipients to live for decades longer than this.2 Pae-
diatric liver transplantation is often performed with adult donor
organs either with a living related donor or with a deceased
reduced liver segment. Do these grafts continue to age at the same
rate, and what are the factors involved in this ageing process?
Cellular senescence
Cellular senescence occurs when a cell does not divide further but
retains the majority of the other abilities of the cell. Telomeres are
a nucleoprotein complex, encoded by DNA segments (TTAGGG)
that are repeated up to thousands of times.3 These repeated seg-
ments are shortened by cell division and thus may confer a
maximal lifespan on a particular cell lineage with cells entering
into a stable state with an arrested cell cycle. The loss of telomere
length to a critical level renders the cell unable to divide as it enters
a replicative senescence phase, a phenomenon known as the
Hayflick limit.4,5 Little is known about the cellular senescence of
transplanted livers, which ideally are required to survive at least as
long as the recipient’s other organs.
There is also the suggestion that the stress of transplantation
accelerates cellular senescence.6–8 In the only study that analysed
long-term liver allografts in the paediatric population, telomere
signal intensity was measured to be significantly lower in the
transplanted organs compared with predicted normal ageing.6
Most of the decline appeared in the first year although there was
no correlation with acute cellular rejection or idiopathic
post-transplant hepatitis. The authors suggest that ischaemia-
reperfusion injury was the likely causative factor.6
With the ageing of transplanted livers, histological damage
increases with up to 43% of asymptomatic patients at 5 years and
64% at 10 years developing chronic hepatitis.9 Up to 97% of grafts
older than 3 years old exhibited some form of fibrosis.10 While
most of this damage appears to be immunologically mediated,
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there is a percentage of patients in whom no cause is identified
and may be a reflection of age-related damage.9–11 This is sup-
ported by evidence suggesting that fibrosis is increased where
there is a high donor-to-recipient age ratio.11In addition, it has
been hypothesized that cellular senescence may be responsible for
some of the long-term deterioration and damage of transplanted
organs.8,12
It is of no surprise that outcomes from older donors are clearly
worse,13,14 but this is not universal. The search is on to findmarkers
that are predictive of function and longevity of transplanted
organs. One such marker is that of telomere length, but not all
replicative cellular senescence is related to telomeres and other
factors may play a role in the ageing of cells.15
With the expansion of gene array analysis, literally hundreds of
gene expression profiles change with age, but unfortunately none
so far have been found to be sensitive or specific for cellular
senescence.15–17 The predominant genetic factors and markers that
have been studied are telomere length, senescence marker
protein-30 (SMP-30) and CDKN2A (p16INK4a).
Telomeres
Cells with critically short telomeres have impaired regenerative
capacity, a function required after the transplantation process as
well as for continued longevity of the organ.18,19 Of importance,
transplantation-related ischaemia has been found to decrease
telomere length.20 Telomeres may shorten through the advance-
ment of age, as well as other processes that damage the cell.21,22
Telomerase activity may help to abrogate this change by adding
telomeric repeats on to the end of chromosomes, but it appears
that this only occurs in foetal livers.23 Four groups have studied the
relationship between telomere length and ageing in humans.6,24–26
In one of the first studies of telomeres in human liver samples
derived from liver resections, Aikata et al. reported a reduction
rate of 120 bp in 23 individuals (aged 17–81 years) with telomere
length reducing to 10 kbp at the age of 80.24 In a separate group of
chronic liver disease patients, they found a minimum telomere
length of around 5 kbp which they suggested may be indicative of
the Hayflick limit. Additionally, this demonstrated that cellular
damage significantly shortened telomeres irrespective of age.
In a study of 73 deceased donor livers (age 5–79 years) per-
formed by Verma et al., age-related telomere shortening was
restricted to Kupffer cells and stellate cells, with cholangiocytes
and hepatocytes being spared of age-related shortening.26 Signifi-
cantly, the authors took great care to highly select these donors to
exclude those with any evidence of senescence-related diseases
(only 8% of the donor population were included).
Takubo et al. studied liver specimens from 94 individuals aged
0–101 years with telomere shortening with age found to be sig-
nificant (55 bp per year).25 The mean telomere length in five neo-
nates was 12.9 kbp, with an estimated telomere length of
approximately 7 kbp at the age of 100. Their data suggested that
telomere length shortened faster before the age of 40 years and
shortened slower in subsequent years, although more data are
required to support this.
Aini et al. attempted to directly answer the question of ageing in
paediatric liver transplants, measuring telomere signal intensity in
17 patients who received a living donor liver transplant.6 Com-
pared with predicted normal ageing, telomere signal intensity was
measured to be significantly lower.6
It must be remembered that these studies have a paucity of
young tissue with which to work and this confounds results.27 The
studies also differ in their calculation of telomere shortening and
this could additionally confound results. While there is little evi-
dence, it appears that telomere shortening is more predominant in
the early years during high tissue turnover and growth, with pos-
sibly only minimal if any telomere shortening in the aged.25,27 This
is supported by studies in other tissues types such as
haematopoietic cells and skeletal muscle.28 Thus, a lack of data in
the early years may partly explain the difference in results in
between these highlighted studies.
SMP-30
SMP-30 was originally discovered by Fujita et al. as a senescence
marker, with expression decreasing by up to 40% in rat livers.29 It
was later found to be identical to regucalcin, a protein that regu-
lates intracellular Ca2+ homeostasis.30–33 A lack of SMP-30may also
lead to liver fibrosis owing to its secondary effect on vitamin C
production.34–36 SMP-30 has also been found to be markedly
reduced in aged zebrafish livers as well as models of hepatectomy
and liver tumours.30
Unfortunately, while there is an abundance of SMP-30 within
the livers of young children, Eguchi et al. have shown quite con-
vincingly that there is minimal if any SMP-30 within the livers of
young human adults which drastically reduces SMP-30s useful-
ness as a biomarker for use in clinical transplantation.37 Addition-
ally, there was no increase in SMP-30 in adult-to-child grafts
suggesting that any senescence or rejuvenation of these grafts
would be SMP-30 independent.
CDKN2A/p16INK4a
CDKN2A (p16INK4a) is a key senescence marker, and has shown to
be associated with ageing as well as transplant-related injury in
kidney transplantation.8,12,38 CDKN2A is a cell-cycle inhibitor and
while is often observed with telomere shortening, is thought to be
independent of this process and is linked to stress-induced senes-
cence.20,39 Most of the literature on CDKN2A in transplantation
has been performed on renal grafts, and the corollary with liver
transplantation is uncertain.
Recently, two independent studies have confirmed CDKN2A to
be a more important predictor of long-term graft function than
donor age and telomere length, with best results using both
p16INK4a and donor age to predict long-term renal transplant
outcome.12,39 Koppelstaetter et al. found telomere length to signifi-
cantly correlate with donor age pre-transplant, however, donor
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age correlated better with function at 1 year than did telomere
length.39 No studies have examined CDKN2A in liver models.
Other markers
There are a range of other biomarkers that have been studied in
the ageing of livers. Cyclooxygenase 1 and 2 (COX-1 and COX-2)
was found in elevated levels in older kidneys and was associated
with higher protein expression.38 As to be expected, the cell pro-
liferation marker Ki-67 was reduced in older organs.38
Endoplasmic reticulum chaperones have been found in reduced
levels in older rat livers, although there were alsomarked swings in
levels between the summer and winter months.40 Dilichol levels
are increased in tissues including the liver and this precedes the
accumulation of altered liver proteins.41 None of these factors have
been further evaluated for their usefulness as a biomarker for
ageing. Reduced anti-oxidant protection with age has been inves-
tigated, however, oxidative damage measured variously by several
groups has not been found to be a significant marker of ageing.42,43
Some metabolic pathways are affected by the ageing process, of
which the most characterized and studied are the insulin and
mTOR pathways.16 Impaired glucose tolerance, however, is neither
specific nor sensitive for ageing. Cytochrome p450 (CYP) mRNA
expression has been found experimentally to correlate highly with
age, with CYP1A2, CYP2B1/2 and CYP3A1 all increased and
CYP2E1 decreased in young hepatocyte proliferation in the con-
dition of hepatocarcinogenesis.44 While this may lead to further
advances in the difference in function between young and old
livers, it is not yet conceivable that these could be markers to aid in
the usability of a potential donor organ and remain firmly as a
scientific model.
In rats, T-kininogen is a gene whose expression markedly
increases in the months prior to death regardless of the actual age
of the rat and appears to be independent of disease.45 Unfortu-
nately, this remarkable gene is not found in humans.
Rejuvenation of liver grafts
Do host factors modify the ageing process in the transplanted
liver? Modification of the recipient environment may be possible
to reverse ageing factors and enhance organ rejuvenation. Conboy
et al., in an elegant parabiotic animal model with anastomosed
mice sharing a blood supply, have shown that hepatic progenitor
cells exposed to the serum of younger patients may reverse age-
related proliferation.46 While this process happens naturally in
adult to paediatric liver transplantation, it remains to be estab-
lished if there are processes that could be augmented to improve
any potential anti-ageing effect.
Conclusion
The aging of organs is a fascinating topic with much still to learn
in the setting of transplantation. With many patients undergoing
post-transplant biopsy, there seems to be ample opportunity to
examine factors that may impact upon cellular senescence and
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